Bausch Health Companies Inc (NYSE:BHC) EVP Christina Ackermann Sells 19,946 Shares

Bausch Health Companies Inc (NYSE:BHC) EVP Christina Ackermann sold 19,946 shares of Bausch Health Companies stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $24.98, for a total transaction of $498,251.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

BHC traded down $0.09 on Friday, hitting $27.20. 3,898,414 shares of the company’s stock were exchanged, compared to its average volume of 4,904,969. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 7.55. The stock has a market cap of $9.48 billion, a PE ratio of 7.10, a price-to-earnings-growth ratio of 0.37 and a beta of -0.28. Bausch Health Companies Inc has a fifty-two week low of $13.86 and a fifty-two week high of $28.45.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.31. The firm had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.09 billion. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The company’s revenue was down 3.7% on a year-over-year basis. As a group, research analysts anticipate that Bausch Health Companies Inc will post 3.7 earnings per share for the current year.

A number of equities research analysts recently issued reports on the stock. HC Wainwright set a $25.00 price target on shares of Bausch Health Companies and gave the company a “hold” rating in a research note on Monday, October 15th. Zacks Investment Research cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Thursday, October 4th. Royal Bank of Canada lifted their target price on shares of Bausch Health Companies from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Wednesday, August 8th. Wells Fargo & Co reaffirmed a “sell” rating on shares of Bausch Health Companies in a research note on Monday, August 6th. Finally, Piper Jaffray Companies set a $13.00 target price on shares of Bausch Health Companies and gave the stock a “sell” rating in a research note on Monday, July 23rd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Bausch Health Companies presently has a consensus rating of “Hold” and a consensus price target of $27.55.

Several hedge funds have recently made changes to their positions in the company. Canada Pension Plan Investment Board acquired a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $38,497,000. Trexquant Investment LP acquired a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $1,904,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $703,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $3,395,000. Finally, Ontario Teachers Pension Plan Board acquired a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $855,000. 42.90% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.baseballdailydigest.com/2018/11/10/christina-ackermann-sells-19946-shares-of-bausch-health-companies-inc-bhc-stock.html.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply